Experiments at the UK's institute of cancer research show that blocking the enzyme LOXL2 prevented metastasis. Their findings were said to be ‘highly likely’ to be used in a clinical setting.
Patients with with breast cancer showed high levels of the enzyme LOXL2 which suggests that the enzyme was linked with cancer spread and poor survival rates.
The enzyme LOXL2 was also shown to be important in the early stages of cancer spread, the enzyme helps cancerous cells escape from the breast tissue into the bloodstream.
In studies with mice the blocking of the enzyme stopped breast cancer spreading, the enzyme was blocked by chemicals and antibodies.
Dr Janine Erler said “LOXL2 is a fantastic drug target, it’s highly likely to be used in a clinical setting.
I found this interesting because it shows good progress in cancer research and relates to our work on enzymes.
http://www.bbc.co.uk/news/health-12525109
Patients with with breast cancer showed high levels of the enzyme LOXL2 which suggests that the enzyme was linked with cancer spread and poor survival rates.
The enzyme LOXL2 was also shown to be important in the early stages of cancer spread, the enzyme helps cancerous cells escape from the breast tissue into the bloodstream.
In studies with mice the blocking of the enzyme stopped breast cancer spreading, the enzyme was blocked by chemicals and antibodies.
Dr Janine Erler said “LOXL2 is a fantastic drug target, it’s highly likely to be used in a clinical setting.
I found this interesting because it shows good progress in cancer research and relates to our work on enzymes.
http://www.bbc.co.uk/news/health-12525109